Use of hospice at end of life is significantly influenced by physician characteristics
the ONA take:
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees, according to new research from Brigham and Women’s Hospital.
This factor outweighs other known factors, including geographic location, patient age, race, and comorbidities.
After controlling for other factors that predict hospice enrollment, the researchers found that patients were 27% more likely to enroll in hospice if they saw a physician in the top 10% of hospice use, compared with those who saw a physician in the bottom 10%. In addition, they found that a large number of cancer patients were seen by a relatively small group of physicians.
Study results also showed that regional factors, greater comorbidity, and physician specialty were significantly associated with the likelihood of hospice enrollment.
A new effect seen in this study was physicians associated with for profit hospitals were less likely to have patients enroll in hospice, compared with physicians with non-profit hospitals.
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|